Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01094821Phase 1Completed

Effect of ATI-7505 on Gastrointestinal Transit in Healthy Volunteers

Role: collaborator

NCT00691470Phase 2Unknown

Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation

Role: lead

NCT00630370Phase 2Terminated

A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome

Role: collaborator

NCT00389792Phase 2Completed

Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers

Role: lead

NCT00431782Phase 2Completed

Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation

Role: lead

All 5 trials loaded